Front Row

Investment decisions are concentrated between co-founders Daniel G. Cohen and Howard Morgan. Cohen brings institutional finance and SPAC expertise from his role at Cohen & Company, while Morgan contributes four decades of angel-investing and venture-fund experience, including co-founding First Round Capital. The firm has not disclosed an external investment committee or third-party advisors in public filings.

Front Row operates as a separate venture capital entity from Cohen & Company, the publicly traded financial services firm where Daniel Cohen serves as Chairman. However, the two entities share an institutional DNA: Front Row portfolio companies may benefit from Cohen & Company's public-market structuring capabilities, including potential SPAC or IPO pathways, though no formal cross-entity commitment has been disclosed.

The firm focuses on seed and early-stage rounds, with capacity for selective follow-on investments into growth equity. Front Row does not publicly specify a check-size range, but its positioning alongside traditional angel syndicates and micro-VCs suggests initial commitments concentrated at the pre-Series A stage.

The firm does not maintain a public exclusion list. Based on its disclosed portfolio patterns, Front Row has not been active in deep-tech hardware, biotech therapeutics, or capital-intensive industrial technology—areas that fall outside the consumer-enterprise-software intersection where the partners' networks are densest.

Front Row invests primarily through direct equity positions in operating companies. There is no public record of the firm committing capital as a limited partner into third-party venture funds, consistent with its lean, partner-led investment model.

The firm has participated in syndicated rounds, reflecting Howard Morgan's long-standing relationships across the venture ecosystem. Front Row does not market a formal co-investment program, but its deal flow relies in part on networks built through Morgan's prior funds and angel portfolio, creating informal co-investment alignment with other early-stage managers.

The firm has not publicly disclosed its limited partner base. Given Daniel Cohen's institutional finance background and the fund's private placement structure, capital likely originates from a mix of institutional allocators, family offices, and high-net-worth individuals—though no specific LP names appear in public records.